Clinical Trial Update: A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of Emricasan, a caspase inhibitor, for chronic hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Emricasan (emricasan)

Snippet

Sponsor: Conatus Pharmaceuticals Inc. | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED